Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Medtronic
Express Scripts
Boehringer Ingelheim
AstraZeneca

Last Updated: August 17, 2022

Investigational Drug Information for Ladarixin


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Ladarixin?

Ladarixin is an investigational drug.

There have been 6 clinical trials for Ladarixin. The most recent clinical trial was a Phase 2 trial, which was initiated on December 21st 2020.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 1, Diabetes Mellitus, and Insulin Resistance. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A and [disabled in preview].

There are ten US patents protecting this investigational drug and eighty-six international patents.

Recent Clinical Trials for Ladarixin
TitleSponsorPhase
Randomized, Double-blind, Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.Dompé Farmaceutici S.p.APhase 2
Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 DiabetesDompé Farmaceutici S.p.APhase 2
A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual β-cell FunctionDompé Farmaceutici S.p.APhase 3

See all Ladarixin clinical trials

Clinical Trial Summary for Ladarixin

Top disease conditions for Ladarixin
Top clinical trial sponsors for Ladarixin

See all Ladarixin clinical trials

US Patents for Ladarixin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ladarixin See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Ladarixin See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
Ladarixin See Plans and Pricing Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA) See Plans and Pricing
Ladarixin See Plans and Pricing Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) See Plans and Pricing
Ladarixin See Plans and Pricing Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ladarixin

Drugname Country Document Number Estimated Expiration Related US Patent
Ladarixin Australia AU2017261372 2036-05-05 See Plans and Pricing
Ladarixin Canada CA3023278 2036-05-05 See Plans and Pricing
Ladarixin China CN107847398 2036-05-05 See Plans and Pricing
Ladarixin European Patent Office EP3452003 2036-05-05 See Plans and Pricing
Ladarixin European Patent Office EP3981392 2036-05-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Medtronic
Express Scripts
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.